197 related articles for article (PubMed ID: 35191358)
1. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
Shah N; Lipato T; Alvarez O; Delea T; Lonshteyn A; Weycker D; Nguyen A; Beaubrun A; Agodoa I
Expert Rev Hematol; 2022 Feb; 15(2):167-173. PubMed ID: 35191358
[TBL] [Abstract][Full Text] [Related]
2. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
Inusa BPD; Mnika K; Babiker S
Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
[TBL] [Abstract][Full Text] [Related]
3. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
5. Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
Galacteros F; Ethgen O; Beillat M
PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228
[TBL] [Abstract][Full Text] [Related]
6. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
7. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
8. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
Green ML; Savic RM; Tonda M; Jorga K; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
[TBL] [Abstract][Full Text] [Related]
9. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
10. Voxelotor for the treatment of sickle cell disease in pediatric patients.
Brown C; Tonda M; Abboud MR
Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
12. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
[TBL] [Abstract][Full Text] [Related]
14. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
15. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
17. Patient perception of voxelotor treatment benefit in sickle cell disease.
Idowu M; Haque A; Williams EM; Sridhar A
J Investig Med; 2022 Jun; 70(5):1316-1319. PubMed ID: 35732337
[TBL] [Abstract][Full Text] [Related]
18. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
19. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Ershler WB; Holbrook ME
Transfusion; 2020 Dec; 60(12):3066-3067. PubMed ID: 32815179
[No Abstract] [Full Text] [Related]
20. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
